A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation

Project: Research

Project Details

StatusActive
Effective start/end date10/12/19 → 9/12/24

Keywords

  • clinical trial
  • phase 3 study
  • treatment efficacy
  • myeloma